GlaxoSmithKline has agreed to pay €33.6 million upfront and to make an equity investment of up to €84 million in Intercell AG in order to gain access to the Austrian company’s needle-free, patch-based vaccine technology. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
